Loading clinical trials...
Loading clinical trials...
A Multicenter, Open-Label, Parallel-Group, Randomized, Flexible Dose Study To Evaluate the Safety and Tolerability of Switching From Existing Atypical Antipsychotics to Bifeprunox in Subjects With Schizophrenia or Schizoaffective Disorder
The study will evaluate the safety and tolerability of switching subjects with schizophrenia or schizoaffective disorder from their existing antipsychotic medication to Bifeprunox.
Age
18 - 65 years
Sex
ALL
Healthy Volunteers
No
Site 148
Birmingham, Alabama, United States
Site 194
Little Rock, Arkansas, United States
Site 178
Anaheim, California, United States
Site 167
Cerritos, California, United States
Site 189
Cerritos, California, United States
Site 183
Culver City, California, United States
Site 140
Garden Grove, California, United States
Site 162
La Palma, California, United States
Site 190
Long Beach, California, United States
Site 173
Oceanside, California, United States
Start Date
December 1, 2006
Primary Completion Date
February 1, 2008
Completion Date
February 1, 2008
Last Updated
May 21, 2008
286
ACTUAL participants
Aripiprazole
DRUG
Olanzapine
DRUG
Risperidone
DRUG
Quetiapine
DRUG
Ziprasidone
DRUG
Aripiprazole
DRUG
Olanzapine
DRUG
Risperidone
DRUG
Quetiapine
DRUG
Ziprasidone
DRUG
Lead Sponsor
Solvay Pharmaceuticals
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions